We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Multiplicom Launches a New Test for the Diagnosis of CLL
Product News

Multiplicom Launches a New Test for the Diagnosis of CLL

Multiplicom Launches a New Test for the Diagnosis of CLL
Product News

Multiplicom Launches a New Test for the Diagnosis of CLL


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Multiplicom Launches a New Test for the Diagnosis of CLL"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Multiplicom N.V. has announced the release of a new gene panel, the CLL MASTR™ Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. This is the most common form of leukemia in adults and has a highly variable outcome. Multiplicom’s test helps to steer the treatment options to stabilize the disease.

Chronic Lymphocytic Leukemia or CLL-patients can experience ‘stable disease’ - the cancer remains the same - over a prolonged period. But at any given time, CLL can progress very fast, requiring appropriate treatment adjustments to keep progression at bay.

Genetic analysis is an important tool in the differential diagnosis and distinguishes between ‘stable disease’ and ‘progression’. The CLL MASTR Plus kit is composed of 9 genes that are frequently mutated in CLL, providing information to guide treatment options.

The CLL MASTR Plus kit allows the detection of single nucleotide variants as well as copy number alterations. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation. This new test enables personalized medicine for patients with CLL.

“The composition of the gene panel was established in collaboration with key opinion leaders in the diagnosis and treatment of CLL. The CLL MASTR Plus kit is based on Multiplicom’s MASTR technology, delivering a simple, fast and affordable genetic test to labs. The MASTR kits are compatible with the leading NGS platforms, and have been subjected to state of the art quality control measures ensuring reproducible results” says Jurgen Del Favero, CTO of Multiplicom.

Advertisement